MCL1 inhibitors S63845/MIK665 plus Navitoclax synergistically kill difficult-to-treat melanoma cells

Mukherjee, N; Skees, J; Todd, KJ; West, DA; Lambert, KA; Robinson, WA; Amato, CM; Couts, KL; Van Gulick, R; MacBeth, M; Nassar, K; Tan, AC; Zhai, ZL; Fujita, M; Bagby, SM; Dart, CR; Lambert, JR; Norris, DA; Shellman, YG

Shellman, YG (corresponding author), Univ Colorado, Sch Med, Dept Dermatol, Anschutz Med Campus,Mail Stop 8127, Aurora, CO 80045 USA.; Shellman, YG (corresponding author), Univ Colorado, Gates Ctr Regenerat Med, Anschutz Med Campus, Aurora, CO 80045 USA.

CELL DEATH & DISEASE, 2020; 11 (6):